Evaluation of Aspirin Use With Cancer Incidence and Survival Among Older Adults in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

Overview

Journal JAMA Netw Open

Publisher American Medical Association

Specialty General Medicine

Date 2021 Jan 15

PMID 33449095

Citations 15

Authors

Holli A Loomans-Kropp

Paul Pinsky

Asad Umar

Affiliations

Soon will be listed here.

Abstract

Importance: Many studies have evaluated the long-term benefits of aspirin use; however, the association of aspirin use with cancer incidence and survival in older individuals remains uncertain. Additional population-based evidence of this association is necessary to better understand any possible protective effects of aspirin in older adults.

Objective: To investigate the association of aspirin use with risk of developing new cancers and site-specific cancer-associated survival in bladder, breast, esophageal, gastric, pancreatic, and uterine cancers.

Design, Setting, And Participants: This cohort study used data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Participants were aged 65 years or older at baseline (1993-2001) or reached age 65 during follow-up. Data analysis was conducted from January to June 2020.

Main Outcomes And Measures: Incidence of and survival from the investigated cancer types. Univariable and multivariable hazard ratios (HRs) and 95% CIs were calculated using Cox proportional hazards regression modeling, adjusting for covariates. Multivariable models for incidence included time-varying covariates.

Results: A total of 139 896 individuals (mean [SD] age at baseline, 66.4 [2.4] years; 71 884 [51.4%] women; 123 824 [88.5%] non-Hispanic White individuals) were included in the analysis. During the study period, 32 580 incident cancers (1751 [5.4%] bladder, 4552 [14.0%] breast, 332 [1.0%] esophageal, 397 [1.2%] gastric, 878 [2.7%] pancreatic, and 716 [2.2%] uterine cancers) were reported. Aspirin use was not associated with incidence of any of the investigated cancer types among individuals aged 65 years or older. Multivariable regression analysis demonstrated that aspirin use at least 3 times/week was associated with increased survival among patients with bladder (HR, 0.67; 95% CI, 0.51-0.88) and breast (HR, 0.75; 95% CI, 0.59-0.96) cancers but not among those with esophageal, gastric, pancreatic, or uterine cancer. A similar association of any aspirin use with bladder (HR, 0.75; 95% CI, 0.58-0.98) and breast (HR, 0.79; 95% CI, 0.63-0.99) cancer survival was observed.

Conclusions And Relevance: In the current study, any aspirin use and aspirin use at least 3 times/week was associated with improved bladder and breast cancer survival. Associations between aspirin use and incidence of any of the investigated cancers or between aspirin use and esophageal, gastric, pancreatic, or uterine cancer survival were not observed.

Citing Articles

Aspirin in Cancer Therapy: Pharmacology and Nanotechnology Advances.

Laila U, Zhao Z, Liu H, Xu Z Int J Nanomedicine. 2025; 20:2327-2365.

PMID: 40017626 PMC: 11866938. DOI: 10.2147/IJN.S505636.

Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women's Health Initiative.

Brasky T, Jager L, Newton A, Li X, Loomans-Kropp H, Hays J Cancer Epidemiol Biomarkers Prev. 2024; 33(9):1203-1210.

PMID: 38900510 PMC: 11371515. DOI: 10.1158/1055-9965.EPI-24-0305.

Yang Y, Zhang Y, Tang Y, Zhang J PLoS One. 2023; 18(12):e0296158.

PMID: 38127958 PMC: 10734918. DOI: 10.1371/journal.pone.0296158.

Using aspirin to prevent and treat cancer.

Lichtenberger L Inflammopharmacology. 2023; 32(1):903-908.

PMID: 38064111 DOI: 10.1007/s10787-023-01346-2.

Aspirin Use and Survival Among Patients With Breast Cancer: A Systematic Review and Meta-Analysis.

Baker A, Kartsonaki C Oncologist. 2023; 29(1):e1-e14.

PMID: 37358878 PMC: 10769789. DOI: 10.1093/oncolo/oyad186.

References

Spence A, Busby J, Johnston B, Baron J, Hughes C, Coleman H . Low-Dose Aspirin Use Does Not Increase Survival in 2 Independent Population-Based Cohorts of Patients With Esophageal or Gastric Cancer. Gastroenterology. 2017; 154(4):849-860.e1. DOI: 10.1053/j.gastro.2017.10.044. View

Bresalier R . Chemoprevention of Barrett's Esophagus and Esophageal Adenocarcinoma. Dig Dis Sci. 2018; 63(8):2155-2162. DOI: 10.1007/s10620-018-5149-6. View

Thorsson V, Gibbs D, Brown S, Wolf D, Bortone D, Yang T . The Immune Landscape of Cancer. Immunity. 2018; 48(4):812-830.e14. PMC: 5982584. DOI: 10.1016/j.immuni.2018.03.023. View

Wang Y, Shen C, Ge J, Duan H . Regular aspirin use and stomach cancer risk in China. Eur J Surg Oncol. 2015; 41(6):801-4. DOI: 10.1016/j.ejso.2015.02.006. View

Zhou C, Daugherty S, Liao L, Freedman N, Abnet C, Pfeiffer R . Do Aspirin and Other NSAIDs Confer a Survival Benefit in Men Diagnosed with Prostate Cancer? A Pooled Analysis of NIH-AARP and PLCO Cohorts. Cancer Prev Res (Phila). 2017; 10(7):410-420. PMC: 5516895. DOI: 10.1158/1940-6207.CAPR-17-0033. View

Johnson C, Hayes R, Schoen R, Gunter M, Huang W . Non-steroidal anti-inflammatory drug use and colorectal polyps in the Prostate, Lung, Colorectal, And Ovarian Cancer Screening Trial. Am J Gastroenterol. 2010; 105(12):2646-55. PMC: 5557093. DOI: 10.1038/ajg.2010.349. View

Stuntz M, Bernstein B . Recent trends in the prevalence of low-dose aspirin use for primary and secondary prevention of cardiovascular disease in the United States, 2012-2015. Prev Med Rep. 2017; 5:183-186. PMC: 5219640. DOI: 10.1016/j.pmedr.2016.12.023. View

Andriole G, Crawford E, Grubb 3rd R, Buys S, Chia D, Church T . Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360(13):1310-9. PMC: 2944770. DOI: 10.1056/NEJMoa0810696. View

Lyon T, Frank I, Shah P, Tarrell R, Cheville J, Karnes R . The Association of Aspirin Use with Survival Following Radical Cystectomy. J Urol. 2018; 200(5):1014-1021. DOI: 10.1016/j.juro.2018.05.119. View

10.

Huang W, Daugherty S, Shiels M, Purdue M, Freedman N, Abnet C . Aspirin Use and Mortality in Two Contemporary US Cohorts. Epidemiology. 2017; 29(1):126-133. PMC: 5718934. DOI: 10.1097/EDE.0000000000000746. View

11.

Husain S, Szabo I, Tamawski A . NSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of action. Am J Gastroenterol. 2002; 97(3):542-53. DOI: 10.1111/j.1572-0241.2002.05528.x. View

12.

Rothwell P, Price J, Fowkes F, Zanchetti A, Roncaglioni M, Tognoni G . Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012; 379(9826):1602-12. DOI: 10.1016/S0140-6736(11)61720-0. View

13.

Andriole G, Crawford E, Grubb 3rd R, Buys S, Chia D, Church T . Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012; 104(2):125-32. PMC: 3260132. DOI: 10.1093/jnci/djr500. View

14.

Holmes M, Chen W, Li L, Hertzmark E, Spiegelman D, Hankinson S . Aspirin intake and survival after breast cancer. J Clin Oncol. 2010; 28(9):1467-72. PMC: 2849768. DOI: 10.1200/JCO.2009.22.7918. View

15.

Algra A, Rothwell P . Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012; 13(5):518-27. DOI: 10.1016/S1470-2045(12)70112-2. View

16.

McNeil J, Nelson M, Woods R, Lockery J, Wolfe R, Reid C . Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. N Engl J Med. 2018; 379(16):1519-1528. PMC: 6433466. DOI: 10.1056/NEJMoa1803955. View

17.

Wang D, DuBois R . Prostaglandins and cancer. Gut. 2005; 55(1):115-22. PMC: 1856377. DOI: 10.1136/gut.2004.047100. View

18.

Rooney M, Shukla S, Wu C, Getz G, Hacohen N . Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015; 160(1-2):48-61. PMC: 4856474. DOI: 10.1016/j.cell.2014.12.033. View

19.

Varn F, Wang Y, Mullins D, Fiering S, Cheng C . Systematic Pan-Cancer Analysis Reveals Immune Cell Interactions in the Tumor Microenvironment. Cancer Res. 2017; 77(6):1271-1282. PMC: 5798883. DOI: 10.1158/0008-5472.CAN-16-2490. View

20.

Khalaf N, Yuan C, Hamada T, Cao Y, Babic A, Morales-Oyarvide V . Regular Use of Aspirin or Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs Is Not Associated With Risk of Incident Pancreatic Cancer in Two Large Cohort Studies. Gastroenterology. 2017; 154(5):1380-1390.e5. PMC: 5880716. DOI: 10.1053/j.gastro.2017.12.001. View